Necrobiosis Lipoidica (Investigational Adjunct)
Investigational adjunct for stable non-ulcerated necrobiosis lipoidica; no clinical leech study was identified; topical corticosteroids remain first-line.
Patient Summary
- Is this FDA-cleared for this use?
- Not FDA-cleared for necrobiosis lipoidica. FDA cleared medicinal leeches only for venous congestion in microsurgical reconstruction (K040187, June 2004). Use here is Tier C investigational.
- What evidence exists?
- Tier C (investigational). No clinical study of leech therapy for necrobiosis lipoidica was identified in our literature search. First-line management of necrobiosis lipoidica, per a German guideline based on case reports and expert consensus, is high-potency topical or intralesional corticosteroid for active borders, optimization of glucose control if diabetic (though this often does not change the skin disease), tight wound care if ulceration occurs, topical tacrolimus, pentoxifylline, and for refractory disease systemic options including biologic anti-TNF therapy or PUVA.
- Main risks
- Bleeding from each bite site for 6 to 10 hours after the leech detaches
- Iron-deficiency anemia from cumulative blood loss across multiple sessions
- Aeromonas hydrophila wound infection from leech gut bacteria (uncommon outside reconstructive surgery, but possible)
- Allergic reaction to leech saliva (rare; ranges from local itching to anaphylaxis)
- Small Y-shaped bite marks or skin colour changes at the bite sites, which usually fade over weeks to months
- Local pain, bruising, swelling, or itching for 1 to 3 days after each session
- Ulceration of fragile necrobiotic skin — up to 30 percent of NL lesions ulcerate spontaneously and may not heal
- Bleeding into atrophic tissue that does not seal normally
- Risk of chronic non-healing bite ulcers
- Infection of ulcerated NL is hard to treat
- Who should not consider this
- Patients with already-ulcerated NL (any new wound may not heal)
- Patients with severely atrophic, telangiectatic lesions
- Patients without optimization of topical corticosteroid trial
- Anyone on blood thinners such as warfarin, apixaban, rivaroxaban, dabigatran or heparin (daily aspirin alone is not a contraindication: tell your doctor, who starts with fewer leeches)
- People with hemophilia or any other inherited bleeding disorder
- Patients with anemia
- People with an active infection at the planned application site
- What to ask your clinician
- Has my diagnosis been confirmed by biopsy and other granulomatous diseases ruled out?
- Have I had a proper trial of topical and intralesional corticosteroid?
- Have pentoxifylline, topical tacrolimus, or biologic therapy been considered?
- What is the risk that bite sites in my skin do not heal?
- What is the published evidence base for leeches in NL specifically?
- What is the wound-care plan if a bite site ulcerates?
- When to seek urgent care
- Bleeding from a bite site that soaks through more than one dressing per hour
- Bleeding that continues more than 24 hours after the leech detached
- Spreading redness, warmth, swelling, pus, or red streaks around any bite site
- Fever over 38.0 C / 100.4 F, chills, or feeling suddenly unwell after a session
- Hives, facial or tongue swelling, throat tightness, or any difficulty breathing
- Sudden weakness, dizziness, fast heart rate, or fainting (possible severe blood loss)
- Non-healing or expanding ulceration in any NL lesion
- Sudden change in a lesion (rule out squamous cell carcinoma developing in chronic NL)
- Spreading redness, warmth, or pus around any lesion
What this does NOT mean
- It does not mean leech therapy is FDA-cleared for necrobiosis lipoidica — the only FDA clearance is venous congestion in microsurgical reconstruction (K040187, June 2004).
- It does not replace topical or intralesional corticosteroid, the standard first-line therapy.
- There is no evidence that it addresses the underlying granulomatous and microvascular pathology.
- It carries a substantial risk of non-healing bite ulcers in this fragile skin.
- No clinical study of leech therapy in NL was identified, so its effect there is unknown.
Safety cross-references
Clinical Profile
- Category
- Dermatological
- ICD-10
- L92.1, E08.620, E09.620, E10.620, E11.620, E13.620
- Safety tier
- High
Evidence Summary
Necrobiosis lipoidica is a granulomatous dermatosis producing yellow-brown atrophic plaques with telangiectasias, classically on the pretibial surfaces, with strong association to diabetes mellitus (though present in non-diabetics). Lesions may ulcerate, particularly after trauma, and ulceration is the principal morbidity. Guideline-listed management rests on case reports and expert consensus, because no randomized controlled trial has demonstrated the efficacy of any treatment (German S1 guideline, 2024): glycemic optimization in diabetes (recommended for general health; its effect on lesion activity cannot be reliably judged), high-potency topical or intralesional corticosteroids for active inflammatory borders, topical calcineurin inhibitors as steroid-sparing, and (refractory) TNF-alpha inhibitors, fumaric acid esters, or pentoxifylline. No clinical study of leech therapy for necrobiosis lipoidica (case report, case series or trial) was identified in PubMed, Europe PMC, OpenAlex or ClinicalTrials.gov, or in Russian- and German-language sources (searched October 2026), and the German S1 guideline does not mention leeches. Direct lesion placement is high-risk for triggering ulceration; no description of uninvolved-skin placement and no efficacy data were found.
Treatment specifics
How many leeches, where they are placed, how long a session lasts, and whether to repeat are clinical decisions made by a qualified provider under institutional protocol — not something to self-administer. Discuss the specifics with a clinician experienced in medicinal leech therapy. (Clinicians: where the society's reference books describe a protocol, it is shown in the clinician view — switch the audience selector in the top bar to “Clinician”.)
Contraindications
- Hemophilia or another bleeding disorder
- Taking anticoagulants (blood thinners such as warfarin or heparin)
- Anemia or suppressed blood formation
- Low blood pressure, shock, collapse or fainting
- Severe wasting (cachexia)
- Intolerance of leeches or a history of severe allergic reactions
- Pregnancy
- Stomach or duodenal ulcer, erosive gastritis
- Acute infectious disease or high fever
- Severe unstable illness, markedly weakened immunity (for example during chemotherapy) or HIV infection
- Drinking alcohol at the time of treatment
- No consent from the patient
- Placement directly on necrobiosis lipoidica plaque (absolute — triggers ulceration)
- Active ulceration of the lesion
- Poorly controlled diabetes (HbA1c >8.5 percent)
- Diabetic peripheral neuropathy with reduced protective sensation at placement site
- Diabetic peripheral arterial disease with ABI <0.6
Related Conditions
Type 2 Diabetes Microvascular Complications (Investigational)
Investigational adjunct for microvascular complications of type 2 diabetes; one small randomized trial in neuropathy plus case reports; glycemic control and standard pharmacotherapy remain primary.
Localized Scleroderma / Morphea (Investigational Adjunct)
Highly investigational adjunct for stable plaque morphea; no RCT evidence; UVA1 phototherapy and methotrexate remain primary for active disease.
Granuloma Annulare (Investigational Adjunct)
Highly investigational adjunct for localized granuloma annulare; no clinical study found; many lesions resolve spontaneously within 1-2 years.
Livedo Reticularis
Investigational use for primary livedo reticularis; no clinical study was identified. Secondary causes (lupus, APLAS) require rheumatology referral.